Aldeyra Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Aldeyra Therapeutics sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Aldeyra Therapeutics: 26 sponsored US clinical trials, 1 recruiting.
Aldeyra Therapeutics sponsors 26 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 25 completed. 10 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye, with 2 trials.
Top-decile sponsor footprint
Aldeyra Therapeutics ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 25 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
NCT07402876
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
NCT06685692
A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06493604
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT06424444
A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)
NCT05717920
A Study in Subjects With Retinitis Pigmentosa
NCT05392179
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
NCT05392192
A Clinical Trial to Evaluate the Safety and Efficacy of ADX-629 in in Subjects With Elevated Ethanol Levels
NCT05487404
The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
NCT05062330
A Clinical Trial to Assess Subjects With Dry Eye Disease.
NCT04971031
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
NCT04908514
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.
NCT04847544
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
NCT04735393
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
NCT04674358
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
NCT04136366
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
NCT03916042
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
NCT03879863
A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
NCT03660878
RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)
NCT03445650
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
NCT03494504
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease
NCT03404115
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
NCT03162783
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
NCT03131154
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
NCT03012165
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
NCT02402309
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
NCT02406209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 14 |
| Phase 3 | 10 |
Therapeutic Areas
What is open in the Aldeyra Therapeutics pipeline
1 recruiting of 26 indexed (4% open); 25 completed (96%).
Phase mix: 10 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Dry Eye (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Aldeyra Therapeutics: open-pipeline peers nationwide
Peers matched on 26 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Aldeyra Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
- Harvard Medical School (HMS and HSDM) · 26 trials · 15% recruiting
Sponsors near 4% open enrollment (± trial volume)
- MaineHealth · 4% recruiting · 26 trials
- Medtronic Spinal and Biologics · 4% recruiting · 26 trials
- Oklahoma State University · 4% recruiting · 26 trials
- ViiV Healthcare · 4% recruiting · 182 trials
Related
What to do with this Aldeyra Therapeutics page
26 registered trials is a research-attention snapshot, not an endorsement of Aldeyra Therapeutics or any single study.
- 1 of Aldeyra Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dry Eye is the condition Aldeyra Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aldeyra Therapeutics pipeline card: 26 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.